Clinical Trial Update: Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3) [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating postoperative adjuvant chemotherapy for thymic cancer (FUSCC-Thymic 3) is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thymic Carcinoma

Snippet

Sponsor: Fudan University | Conditions: Thymic Carcinoma | Phase 3 | Status: RECRUITING